Low-Molecular-Weight Heparin vs Warfarin for Thromboprophylaxis in Children with Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial.

Authors

Cedric Manlhiot
Jane W Newburger
Tisiana Low
Nagib Dahdah
Andrew S Mackie
Geetha Raghuveer
Therese M Giglia
Frederic Dallaire
Mathew Mathew
Kyle Runeckles
Elfriede Pahl
Ashraf S. Harahsheh, George Washington UniversityFollow
Kambiz Norozi
Sarah D de Ferranti
Kevin Friedman
Anji T Yetman
Shelby Kutty
Tapas Mondal
Brian W McCrindle

Document Type

Conference Proceeding

Publication Date

7-1-2020

Journal

The Canadian Journal of Cardiology

DOI

10.1016/j.cjca.2020.01.016

Comments

Online ahead of print

APA Citation

Manlhiot, C., Newburger, J., Low, T., Dahdah, N., Mackie, A., Raghuveer, G., Giglia, T., Dallaire, F., Mathew, M., Runeckles, K., Pahl, E., Harahsheh, A. S., Norozi, K., de Ferranti, S., Friedman, K., Yetman, A., Kutty, S., Mondal, T., & McCrindle, B. (2020). Low-Molecular-Weight Heparin vs Warfarin for Thromboprophylaxis in Children with Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial.. The Canadian Journal of Cardiology, (). http://dx.doi.org/10.1016/j.cjca.2020.01.016

Peer Reviewed

1